Trial results

Trial of Tirzepatide for the Treatment of Cannabis Use Disorder

NCT07468552 on ClinicalTrials.gov · last registry update 2026-03-12

Registered but not yet open, with 100 participants planned. Due to report 15 March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Maximum Tolerated Dose (MTD). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for substance use — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

National Institute on Drug Abuse (NIDA)

Sponsor type

Nih

Enrollment

100

Started

2026-11-15

Primary completion

2028-03-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Maximum Tolerated Dose (MTD)

Conditions studied

Cannabis Use Disorder

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.